avelumab
Selected indexed studies
- Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. (N Engl J Med, 2020) [PMID:32945632]
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. (N Engl J Med, 2019) [PMID:30779531]
- Avelumab in gastric cancer. (Immunotherapy, 2019) [PMID:31060469]
_Worker-drafted node — pending editorial review._
Connections
avelumab is a side effect of
Sources
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. (2019) pubmed
- Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. (2020) pubmed
- Avelumab in gastric cancer. (2019) pubmed
- Avelumab in locally advanced or metastatic urothelial carcinoma. (2022) pubmed
- Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up. (2023) pubmed
- Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. (2021) pubmed
- Avelumab First-Line Maintenance Therapy: Managing Patients With Advanced Urothelial Carcinoma. (2023) pubmed
- Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. (2021) pubmed
- Avelumab as First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma. (2023) pubmed
- Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. (2020) pubmed